- JP-listed companies
- D.Western Therapeutics Institute, Inc.
- Income statement
D.Western Therapeutics Institute, Inc. (4576) Income statement
Market cap
¥5.2B
P/E ratio
-6.4x
De Western Therapeutics Institute develops protein kinase inhibitor drugs for eye diseases and licenses them to pharmaceutical companies for commercialization.
| 2011/12 | 2012/12 | 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Revenue | 20 | 113 | 80 | 80 | 62 | 168 | 254 | 293 | 581 | 356 | 414 | 448 | 428 | 472 | 388 |
| Revenue growth (%) | - | ||||||||||||||
| Cost of revenue | - | - | - | - | - | 6 | 7 | 14 | 26 | 17 | 20 | 28 | 37 | 47 | 39 |
| Gross profit | - | - | - | 80 | 62 | 162 | 247 | 279 | 555 | 339 | 394 | 421 | 392 | 425 | 349 |
| Gross margin (%) | - | - | - | ||||||||||||
| Operating margin (%) | - | - | - | ||||||||||||
| Operating expenses | - | - | - | 277 | 352 | 482 | 880 | 1,066 | 437 | 604 | 566 | 726 | 1,190 | 1,634 | 969 |
| Operating income | - | - | - | -197 | -291 | -320 | -634 | -786 | 117 | -266 | -172 | -306 | -799 | -1,210 | -620 |
| Income before tax | -354 | -255 | -221 | -192 | -295 | -304 | -669 | -797 | 110 | -290 | -160 | -296 | -796 | -1,228 | -630 |
| Pretax margin (%) | -1,768.4 | -226.8 | -276.5 | -239.5 | -477.8 | -181.2 | -263.3 | -272.1 | 18.9 | -81.4 | -38.5 | -66 | -185.9 | -260.4 | -162.7 |
| Provision for income taxes | - | - | - | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Effective tax rate (%) | - | - | - | ||||||||||||
| Net income | -355 | -256 | -222 | -193 | -296 | -254 | -1,563 | -749 | 133 | -276 | -149 | -430 | -812 | -1,290 | -632 |
| Earnings per share | -20.46 | -14.49 | -10.49 | -8.47 | -12.99 | -10.46 | -59.89 | -28.51 | 5.07 | -10.16 | -5.08 | -14.5 | -25.56 | -36.74 | -13.19 |
| Dividend per share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |